期刊文献+

流式细胞免疫表型测定在诊断骨髓增生异常综合征中的意义 被引量:3

Role of Flow Cytometric Immunophenotyping in Diagnosis of Myelodysplastic Syndromes——Review
下载PDF
导出
摘要 应用骨髓和外周血的形态学及细胞遗传学检查可对有明确病态造血和异常核型的骨髓增生异常综合征(MDS)患者做出诊断。然而,仍有相当数量的患者缺乏上述证据。最近的一些研究表明,可以应用流式细胞仪(FCM)检测MDS患者骨髓造血细胞表面免疫标记以反映其系特异性和阶段特异性紊乱,从而将MDS与其他非恶性血细胞减少性疾病区分开。本文对这一领域的相关研究进展,诸如FCM在MDS中的应用、FCM参数与MDS形态学及细胞遗传学诊断的相关性及FCM参数与MDS分型和预后的关系等进行了综述。 Bone marrow morphology and karyotyping are effective ways to diagnose myelodysplasitic syndromes. However, there are still many patients without these two abnormalities. Recently, there are considerable amount of evidence showing that flow cytometric immunophenotyping is a good approach to detect the abnormal differentiation and maturation of different cell lines and maturation stages of bone marrow cells in MDS patients. The highly reproducible results allow to distinguish MDS from other non-clonal hematocytopenia disorders and have a diagnostic advantage especially in case of low-risk MDS. Meanwhile, it showed a good correlation with the morphology and karyotyping, and with the International Prognostic Scoring System (IPSS) playing a prognostic role. This article reviewed recent advances of reseach in this field such as the application of FCM in MDS detection, the correlation of FCM parameters with morphologic and cytogenetic diagnosis of MDS as well as the relationship of parameters with typing and prognosis of MDS and so on.
作者 张言 李晓
出处 《中国实验血液学杂志》 CAS CSCD 2008年第6期1477-1481,共5页 Journal of Experimental Hematology
关键词 骨髓增生异常综合征 流式细胞术 免疫袁型 myelodysplastic syndrome flow cytometry immunophenotype
  • 相关文献

参考文献26

  • 1Alessandrino EP, Amadori S, Cazzola M, et al. Myelodysplastic syndromes : recent advances. Haematologica, 2001 ; 86 : 1124 - 1157 被引量:1
  • 2Marisavljevic D, Cemerikic V, Rolovic Z, et al. Pathohistological characteristics of myelodysplastic syndromes: diagnostic and prognostic significance. Srp Arh Celok Lek, 2005 ; 133 : 162 - 169 被引量:1
  • 3Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982; 51:189 - 199 被引量:1
  • 4Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002 ; 100 : 2292 -2302 被引量:1
  • 5Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol, 2005 ; 23 : 7594 - 7603 被引量:1
  • 6Schmitt-Graeff A, Mattern D, Kohler H, et al. Myelodysplastic syndromes ( MDS), Aspects of hematopathologic diagnosis. Pathology, 2000; 21:1 -15 被引量:1
  • 7邓家栋等主编..邓家栋临床血液学[M].上海:上海科学技术出版社,2001:1714.
  • 8Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res, 2007;31:727-736 被引量:1
  • 9Loken MR, Van-de-Loosdrecht A, Ogata K, et al. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res, 2008 ;32:5 - 17 被引量:1
  • 10Stachurski D, Smith BR, Pozdnyakova O, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res, 2008; 32:215 -224 被引量:1

同被引文献31

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部